Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients.
EORTC QLQ-MY20
interpretation guidelines
meaningful change
minimally important difference
mixed methods
multiple myeloma
qualitative interviews
quality of life
responder definition
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
23
05
2019
revised:
14
08
2019
accepted:
15
08
2019
pubmed:
25
8
2019
medline:
15
2
2020
entrez:
25
8
2019
Statut:
ppublish
Résumé
Thresholds for the minimally important difference (MID) or responder definition (RD) in health-related quality-of-life (HRQoL) scores are required to interpret the impact of an intervention or change in the trajectory of the condition which is meaningful to patients. This study aimed to establish MID and RD for the European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma questionnaire (EORTC QLQ-MY20). A novel mixed-methods approach was applied by utilizing both existing clinical trial data and prospective patient interviews. Anchor-based, distribution-based, and qualitative-based estimates of meaningful change were triangulated to form recommended RDs for each scale of the EORTC QLQ-MY20. Anchor-based MIDs were summarized using weighted correlation. Recommended MIDs were as follows: Disease Symptoms (DS 10 points), Side Effects of Treatment (SE 10 points), Body Image (BI 13 points), and Future Perspective (FP 9 points). Recommended RDs were as follows: DS (16 improvement; 11 worsening), SE (6 improvement; 9 worsening), BI (33 improvement; 33 worsening), and FP (11 improvement; 11 worsening). The study generated estimates of the MID and RD for each scale of the EORTC QLQ-MY20. Published estimates will enable investigators and clinicians to adopt these as standard for interpretation and for hypothesis testing. Consequently, analyses from trials of different interventions can be more comparable.
Identifiants
pubmed: 31444815
doi: 10.1111/ejh.13316
pmc: PMC6852250
doi:
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
500-509Subventions
Organisme : Amgen
Informations de copyright
© 2019 The Authors. European Journal of Haematology Published by John Wiley & Sons Ltd.
Références
Leukemia. 2013 Oct;27(10):1959-69
pubmed: 23783393
PLoS One. 2014 Dec 04;9(12):e114468
pubmed: 25474472
Arch Phys Med Rehabil. 2005 Dec;86(12):2270-6
pubmed: 16344022
Clin Ther. 2016 Apr;38(4):759-68
pubmed: 27041406
Eur J Haematol. 2019 Nov;103(5):500-509
pubmed: 31444815
BMJ Open. 2018 Jan 10;8(1):e019117
pubmed: 29326191
Lancet Oncol. 2016 Jan;17(1):27-38
pubmed: 26671818
Health Qual Life Outcomes. 2018 Oct 19;16(1):202
pubmed: 30340599
J Clin Epidemiol. 1997 Aug;50(8):869-79
pubmed: 9291871
Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):171-84
pubmed: 21476819
Asia Pac J Clin Oncol. 2014 Jun;10(2):109-17
pubmed: 23551530
Value Health. 2011 Dec;14(8):978-88
pubmed: 22152166
Blood Cancer J. 2017 Mar 17;7(3):e543
pubmed: 28304402
Eval Health Prof. 2005 Jun;28(2):172-91
pubmed: 15851772
J Clin Epidemiol. 2008 Feb;61(2):102-9
pubmed: 18177782
Blood. 2019 May 2;133(18):1953-1963
pubmed: 30819926
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Haematologica. 2013 May;98(5):784-8
pubmed: 23242595
J Clin Oncol. 2016 Nov 10;34(32):3921-3930
pubmed: 27601539
Support Care Cancer. 2011 Nov;19(11):1753-60
pubmed: 20886240
Control Clin Trials. 1989 Dec;10(4):407-15
pubmed: 2691207
Health Qual Life Outcomes. 2018 Dec 11;16(1):228
pubmed: 30537955
J Clin Epidemiol. 2011 May;64(5):507-16
pubmed: 21447427
J Clin Epidemiol. 2010 Jan;63(1):37-45
pubmed: 19540720
Qual Life Res. 2002 May;11(3):207-21
pubmed: 12074259
Eur J Cancer. 2007 Jul;43(11):1670-8
pubmed: 17574838
Br J Haematol. 1999 Mar;104(3):605-11
pubmed: 10086801
Eur J Haematol. 2010 Apr;84(4):345-53
pubmed: 20041946